Currently showing only Science & Technology Resources
Page 4 of 7

Rethink public engagement for gene editing

Publication date: 12/03/2018

Over the past three years, thousands of articles have been published about editing genes and genomes. Apart from a public dialogue run by the Royal Society at the end of last year, there’s been little attempt to engage the public on the implications of the technology in a way that could alter the decisions of scientists and policymakers. Indeed, concern about the lack of effective public engagement has motivated several workshops, including one by the intergovernmental Organisation for Economic Co-operation and Development (OECD).

If the history of public engagement surrounding other recent scientific innovations is a guide, efforts to explain the science behind gene editing will intensify, such as through news stories, at science festivals, in public lectures and in museums. And there will be a rash of small, disconnected workshops involving members of the public that are designed to inform specific policy decisions.

If this is all that happens, scientists and policymakers will be ill prepared for the public debate that will almost certainly erupt as applications proliferate.

  • Linked page includes option for .pdf download.
Resource type: article: Web Page

The gene-editing conversation

Publication date: 31/01/2018

In 2014 biochemist Jennifer Doudna of the University of California at Berkeley awoke from a nightmare that would shift the focus of her world-class scientific career. Two years earlier, with her colleague Emmanuelle Charpentier, now director of the Max Planck Unit for the Science of Pathogens in Berlin, Doudna had achieved one of the most stunning breakthroughs in the history of biology, becoming the first to use a process called CRISPR-Cas9 to alter the genetic makeup of living organisms. Their “gene-editing” tool would allow scientists to efficiently insert or delete specific bits of DNA with unprecedented precision.

But as applications related to modifying human genes were soon reported in the scientific literature, Doudna began to worry. In the dream, a colleague asked if she would help teach someone how to use CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats). She followed him into a room to be greeted by Adolph Hitler wearing a pig face. The nightmare reinforced her belief that public discussion of the technology was far behind the breakneck pace of its emerging applications. She feared a public backlash that would prevent beneficial forms of gene-editing research from moving forward.

Resource type: article: Web Page

Compatibility of breeding techniques in organic systems

Publication date: 01/01/2018

This IFOAM position paper states that “New genetic engineering technologies …are not compatible with organic farming and must not be used in organic breeding or organic production.” It goes on to list the specific techniques, and calls for “clear legal definitions to be in place which are regularly updated”.

The paper also states “Products obtained through genetic engineering processes should not be released into the environment. In any case such releases should not take place without a prior rigorous, multistakeholder designed and agreed risk assessment protocol that includes input from the organic sector and like-minded movements, and an assessment of the possibility to prevent the presence of such products in organic products and GMO-free products.”

IFOAM asks for the ‘Polluter Pays’ principle to be maintained. This means “On-going costs and harms to organic and non-GMO supply chains from contamination by these new techniques … should be borne by the developers and/or the company that puts the product on the market.” Although the principle is one of the EU directives, sadly it is not guaranteed in post-Brexit Britain.

Resource type: article: Web Page

New genetic engineering techniques: precaution, risk, and the need to develop prior societal technology assessment

Publication date: 18/08/2017

Business has been arguing that governments should override the precautionary principle in favor of an “innovation principle.” The new genetic engineering techniques (sometimes called “new breeding techniques”)1 provide the perfect cover for this argument. Proponents assure us that these new techniques are essential to address the crises we face and will provide economic benefit, as long as we set aside the precautionary approach that they claim increasingly hampers technological progress. We are in the midst of powerful high-risk technological developments with potentially severe and irreversible health, environmental, and societal implications. It is vital to develop processes for examining new technologies while they are still being developed. We argue that precaution needs to guide technology development in this area. Indeed, it should precede the technology development. An adequate technology assessment and decision-making process requires concerted effort, courage, and restraint, and it must include the option to decide against developing or deploying some technologies altogether.

Resource type: Adobe Acrobat (.pdf)

Addressing socio-economic and ethical considerations in biotechnology governance: the potential of a new politics of care

Publication date: 01/06/2017

There is a growing demand to incorporate social, economic and ethical considerations into biotechnology governance. However, there is currently little guidance available for understanding what this means or how it should be done.

A framework of care-based ethics and politics can capture many of the concerns maintaining a persistent socio-political conflict over biotechnologies and provide a novel way to incorporate such considerations into regulatory assessments. A care-based approach to ethics and politics has six key defining features.

These include: 1) a relational worldview, 2) an emphasis on the importance of context, 3) a recognition of the significance of dependence, 4) an analysis of power, including a particular concern for those most vulnerable, 5) a granting of weight to the significance of affect, and 6) an acknowledgment of an important role for narrative. This policy brief provides an overview of these defining features, illustrates how they can appear in a real world example and provides a list of guiding questions for assessing these features and advancing a politics of care in the governance of biotechnology

Resource type: Adobe Acrobat (.pdf)

Forcing consensus is bad for science and society

Publication date: 12/05/2017

The March for Science that took place in cities around the world on April 22 was intended to “speak for science”, defending evidence-based policies, the strength of peer-reviewed facts and government-funded research.

The marches reflect a growing trend. In February 2017, the text Ethics & Principles for Science & Society Policy-Making, known as the Brussels declaration, was adopted at the American Association for the Advancement of Science’s annual meeting, in Boston. And both the OECD and UNESCO have recently published documents supporting the role of science in informing policy.

Open dialogue between scientists and the societies in which they live and work is, of course, an essential ingredient of democracy. But insisting that science operate under a mandate of consensus, which is the timbre of numerous debates, from vaccines to climate change to genetically modified organisms (GMOs), is not.

Faux unanimity in science actually underexposes policy-relevant scientific and political dissent.

The risks of scientism

Critics of the March for Science, ourselves included, have noted that the march’s program is dangerously close to “scientism” – the adoption of science as a worldview or a religion to the exclusion of other viewpoints.

In doing so, both the march and agreements such as the Brussels declaration ignore the deep crisis facing science, with its daily bulletin of casualties.

Nor is it a good sign that few are reflecting on the power asymmetries that taints what science is used in policy: citizens can’t easily create scientific knowledge, while corporate interests can and do. And evidence has become a currency used by lobbies to purchase political influence.

On the issue of climate change, most scientists have likely formed the opinion that humanity is basically conducting a large-scale geophysical experiment with the planet by increasing the concentration of greenhouse gases.

The problem is not that thesis (it’s essentially correct) but that it is been presented as the scientific consensus concerning the proposed strategy for phasing out fossil fuels. Reasonable minds can differ on the urgency or the feasibility of the strategy for mitigating global warming.

This is one reason why observers on both sides of the “act now!” versus “wait and see” camps can’t agree on how to tame the doubt hounding both climate research and effective responses to the challenge.

What climate, vaccines and GMOs have in common

Childhood vaccination is another hotly contested topic, and the controversy around them has flared for two decades. It started with a paper published in The Lancet in 1998 – later retracted – that purported to show links between vaccines and autism.

The controversy is as fierce as ever today thanks to the involvement of US President Donald Trump and his entourage.

We support vaccination. But we cannot overlook that science holds the responsibility for both starting the scare and for taking a long time to correct its errors. It is unfortunate that we (and others) need to exhibit pro-vaccine credentials in order to attempt a meaningful discussion.

It is also regrettable that vaccines end up being mentioned in same sentence as climate and GMOs. The frequent implication is that science is not the problem but rather the people, who, lacking the knowledge necessary to formulate a clear judgement, end up resisting scientific facts.

This perpetuates the so-called deficit model, an old theory that blames the lay public’s ignorance of science for many problems in the adoption of evidence-based policies.

Golden rice and crimes against humanity

Should science speak with one voice? It did, without doubt, last year when 107 Nobel laureates signed an open letter accusing the environment organisation Greenpeace of crimes against humanity for delaying the commercialisation of a genetically modified rice variety called golden rice.

The Nobel laureates argued that golden rice, which is high in beta carotene, has the potential to “reduce or eliminate much of the death and disease caused by a vitamin A deficiency” and possibly avoid the one to two million “preventable deaths [that] occur annually as a result of this nutritional imbalance”.

Some observers stressed the gravity of the accusations, while prominent journals such as Science and Nature downplayed the letter.

Either way, its content is, frankly, incendiary (more extracts here). In addition to the above claims, the laureates asserted that Greenpeace has “spearheaded opposition” to golden rice. “Opposition based on emotion and dogma contradicted by data must be stopped”, they wrote. “How many poor people in the world must die before we consider this a ‘crime against humanity’?”

Many claims in the letter are either patently false or highly contended. Even the thesis that golden rice is an instrument in the battle against vitamin A deficiency is questionable, according to the International Rice Research Institute. The enhanced beta carotene content of the crop appears to be variable and its value possibly reduced by cooking. Its effectiveness merits further study.

Other scientists have pointed out that vitamin deficiencies are more efficiently fought with better nutrition, direct supplementation, nutrition education programs, the promotion of home gardens, or with the enrichment of staple food with essential nutrients such as vitamin A. All these policies have been implemented successfully over the past decade in many countries.

Golden rice is also a poor solution for vitamin A deficiency because of its lower yield compared to other rice varieties, which could deter farmers from growing it. This is one of the reasons why golden rice is not yet approved for commercialisation.

Finally, its yellow colour makes it more difficult to detect contamination from a dangerous mycotoxin that can cause serious health problems in humans.

All of which is to say that claiming that the introduction of the crop in Asia and Africa by early 2000 would have been beneficial and saved lives is doubtful at best. The evidence does not even contradict the alternative conclusion: that the delayed commercialisation was actually better for the populations concerned.

Safe or fair?

GMOs are a battlefield showing how the issue of framing – deciding on the nature of the problem – is of paramount importance.

For two decades, we have been told that GMOs are safe for human consumption. The tunnel vision on food safety has led to the neglect of other legitimate inquiries on, say, issues of the power, regulation and control of the genetic fabric of our food. Such issues are central to why many constituencies opposed GMO crops.

Relevant, too, and also under discussed, are lessons from unsuccessful GMO adoption.

Today, increasingly more voices are asserting that new technologies should be regulated not only on their benefit-risk profiles but also on their societal context and need, and searching The Conversation for “golden rice” returns a wealth of opinions, indeed – the opposite of a consensus.

This happens because science is a “show me”, not a “trust me”, field. Purporting to speak on behalf of all science, as the Nobel laureates sought to do with golden rice, conflated science, the scientific method and truth.

We live in times of intense ideological confrontations surrounding scientific work. The notion that science works for a common good, which is occasionally imbued with the prestige and authority of Nobel Prize winners, is reassuring. But it is dangerous.

“Science is strictly impersonal; a method and a body of knowledge,” wrote the sociologist John Dewey in the 1930s. “It owes its operation and its consequences to the human beings who use it. It adapts itself passively to the purposes and desires which animate these human beings.”

Dewey called the problem involved in our control of science “the greatest which civilisation has ever had to face”. This calls for a vigilant society and a scientific field that never tires of being critical of itself.

 

This article first appeared in The Conversation and is reprinted here with permission.

Resource type: Word Document (.doc)

Not just about “the science” – science education and attitudes to genetically modified foods among women in Australia

Publication date: 08/02/2017

Previous studies investigating attitudes to genetically modified (GM) foods suggest a correlation between negative attitudes and low levels of science education, both of which are associated with women.

In a qualitative focus group study of Australian women with diverse levels of education, we found attitudes to GM foods were part of a complex process of making “good” food decisions, which included other factors such as locally produced, fresh/natural, healthy and nutritious, and convenient. Women involved in GM crop development and those with health science training differed in how they used evidence to categorize GM foods.

Our findings contribute to a deeper understanding of how GM food, and the role of science and technology in food production and consumption more broadly, is understood and discussed amongst diverse “publics” and across different “sciences,” and to research related to deepening public engagement at the intersection of science and values.

Resource type: Web page URL

Post Note – Genome editing

Publication date: 23/11/2016

Genome editing techniques enable the targeted modification of DNA sequences within living cells. They have potential uses in biomedical research, human therapy, agriculture and to help control vector-borne diseases. This POSTnote covers current and future uses of genome editing, how it is regulated and the potential concerns that it raises.

Website has link to full report.

Resource type: article: Web Page

Why Frankenstein is a great science policy guide for the guture

Publication date: 27/10/2016

Mary Shelley’s 200-year-old fable explores the tension between scientific creativity and social responsibility.

It is a nuanced exploration of scientific ethics and the dynamic between scientific creativity and social responsibility. The novel isn’t a straightforward warning to stop innovating; it is a cautionary tale. The dangers aren’t so much about what we do, but how we go about doing it.

Shelley’s narrative urges us to be good caretakers of the new things we bring into the world, whether they’re ideas or works of art or gadgets or synthetic beings. The novel cautions us that human creativity begets things of great power, and dramatizes what happens when a creator significantly shirks his responsibility.

We’re still grappling with these same issues of creativity and responsibility—even if our scientific knowledge and technological sophistication are far more advanced today than in Shelley’s early 19th century. In an age of obviously Frankensteinian breakthroughs in genetic engineering, artificial intelligence, and social robotics, we’ve already answered the simpler question—we’re being hubristic, in some sense, playing with the forces of life and death. What remains is the deeper lesson at the heart of Frankenstein: That the thrill of discovery is just the beginning of a creator’s work.

Resource type: article: Web Page

Genome-editing – an ethical view

Publication date: 30/09/2016

It seems as though genome editing is everywhere. In a relatively short time, particularly since the emergence of the CRISPR-Cas9 system in 2012, techniques for making precisely targeted
alterations to DNA sequences in living cells have not only preoccupied life science journals, but have also featured in mainstream news. They have been implicated in stories of revolutionary
medical advance and genetically altered food, and in the business pages, where the battle over the intellectual property rights to the underlying technology, and the prospects of companies
developing genome editing treatments and products, have been matters of continual intrigue and speculation.

While the scientific merits are overt, the practical and ethical significance of these recent developments is far harder to discern. While the use of genome editing techniques has spread
across biological research, including microorganisms, plants, animals and human cells, the extent to which the potential applications can be understood in relation to prevailing norms and managed through existing governance measures has not been extensively examined. As a rapidly established (though continually developing) research technique, one that is at the foundation of diverse emerging biotechnologies, there is concern that genome editing science and innovation are moving ahead of public understanding and policy.

The Nuffield Council’s terms of reference charge it “to identify and define ethical questions raised by recent advances in biological and medical research in order to respond to, and to anticipate, public concern.” In 2015, convinced that genome editing had the potential to raise such questions, the Council agreed to undertake a programme of work and established an interdisciplinary working group to gather evidence and to deliberate in relation to these matters. The present publication is the output of the first stage of this work. It addresses conceptual and descriptive issues regarding genome editing and identifies the key ethical questions that arise.

Web page has links to the full report.

Resource type: article: Web Page